Aurora Cannabis shareholders should take the Organigram deal, analyst says

TD Cowen analyst Derek Lessard recommends Aurora Cannabis shareholders accept Organigram Global’s (Organigram Global Stock Quote, Chart, News, Analysts, Financials TSX:OGI) $561-million takeover offer, saying the proposed transaction provides greater certainty than a competing bid from Curaleaf while offering potential upside through ownership of the combined company.

Lessard downgraded the Edmonton-based cannabis producer to “Sell” from “Buy” and lowered his target to $7.80 from $8.00 to reflect Organigram’s offer price.

“In our view, Organigram offers a potentially cleaner path to value realization than Curaleaf despite a similar headline price: cash up front, less balance-sheet risk on the equity portion, and a combination linking Aurora’s EU-GMP supply with Sanity’s German commercial platform,” Lessard said in his Nov. 5 analysis.

Organigram announced Nov. 3 that it had agreed to acquire Aurora for approximately $561-million, following Aurora’s rejection of Curaleaf’s hostile takeover bid. Aurora shareholders can elect to receive $7.80 in cash, 5.8626 Organigram shares, or $3.75 in cash plus 3.0431 Organigram shares for each Aurora share, subject to proration.

Lessard said the cash alternative offers shareholders greater certainty about the value they will receive, while the equity option provides exposure to a larger international cannabis business.

“Organigram is essentially debt-free,” he said. “This provides shareholders, who elect stock exposure to the combined company, with both equity upside and less financing uncertainty.”

The acquisition would combine Aurora’s medical cannabis operations in Canada, Europe, Australia and New Zealand with Organigram’s Canadian recreational business and the European operations of Sanity Group, which Organigram acquired earlier this year. Lessard said the combination is particularly attractive in Germany, where Aurora’s pharmaceutical-grade cannabis production could help address supply constraints facing Sanity’s distribution network.

“Aurora brings EU-GMP expertise and consistent medical supply, while Sanity adds branding, patient acquisition, and pharmacy/telemedicine relationships,” he said. “Organigram management acknowledged EU-GMP supply constraints, so this deal should address a bottleneck.”

The combined company would operate five facilities certified under European Union Good Manufacturing Practice standards, strengthening its ability to supply regulated medical cannabis markets.

Management has identified more than $50-million in potential efficiencies, which Lessard believes could extend beyond eliminating overlapping expenses.

“Beyond public-company costs and overlapping SG&A, opportunities include better German supply, adding Organigram products to Aurora’s Canadian medical platform, and applying Aurora’s EU-GMP expertise to Organigram’s facilities,” he said.

The acquisition’s cash component will be financed through existing funds, a $187.5-million private placement by British American Tobacco and expanded credit facilities with ATB Financial. BAT, an existing strategic shareholder in Organigram, will purchase 141 million shares at $1.33 each, increasing its ownership to approximately 42% on a partially diluted basis following the transaction.

Lessard said BAT’s financial support provides additional confidence in the transaction and could help the combined company pursue further international growth.

The analyst also believes the acquisition could encourage additional consolidation in Canada’s cannabis industry.

“We believe the broader Canadian cannabis read-through is also positive,” Lessard said. “As we’ve noted, this deal could spur further consolidation, particularly around strong cultivation assets and healthy balance sheets. Those that made tough choices early look well-positioned.”

He said the acquisition values Aurora at approximately 17 times his fiscal 2028 EBITDA estimate, suggesting buyers are willing to pay a premium for established cannabis operations with strong assets and international market access.

The transaction remains subject to shareholder, court and regulatory approvals.

-30-